Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Zenas BioPharma, Inc. (ZBIO) had Return on Tangible Equity of -156.00% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$10.00M |
|
$-377.74M |
|
-- |
|
$10.00M |
|
$393.06M |
|
$-383.06M |
|
$5.24M |
|
$-377.82M |
|
$-377.82M |
|
$-377.74M |
|
$-377.74M |
|
$-377.74M |
|
$-377.74M |
|
$-383.06M |
|
$-383.00M |
|
44.73M |
|
44.73M |
|
$-8.44 |
|
$-8.44 |
|
| Balance Sheet Financials | |
$351.17M |
|
$0.03M |
|
$32.47M |
|
$383.64M |
|
$62.65M |
|
$78.64M |
|
$78.85M |
|
$141.50M |
|
$242.14M |
|
$242.14M |
|
$242.14M |
|
54.49M |
|
| Cash Flow Statement Financials | |
$-172.33M |
|
$-251.89M |
|
$215.28M |
|
$319.83M |
|
$110.64M |
|
$-209.19M |
|
$26.35M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.61 |
|
-- |
|
-- |
|
0.25 |
|
0.32 |
|
100.00% |
|
-3830.57% |
|
-3830.57% |
|
-3830.01% |
|
-3778.16% |
|
-3777.37% |
|
$-172.35M |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
-- |
|
-- |
|
-- |
|
-156.00% |
|
|
Return on Tangible Equity |
-156.00% |
-98.46% |
|
-117.76% |
|
$4.44 |
|
$-3.85 |
|
$-3.85 |
|